Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Common Equity (2016 - 2025)

Historic Common Equity for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $232.7 million.

  • Theravance Biopharma's Common Equity rose 2533.05% to $232.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $232.7 million, marking a year-over-year increase of 2533.05%. This contributed to the annual value of $175.5 million for FY2024, which is 1758.26% down from last year.
  • Latest data reveals that Theravance Biopharma reported Common Equity of $232.7 million as of Q3 2025, which was up 2533.05% from $224.8 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Common Equity registered a high of $480.6 million during Q3 2022, and its lowest value of -$373.2 million during Q1 2021.
  • In the last 5 years, Theravance Biopharma's Common Equity had a median value of $193.7 million in 2024 and averaged $72.6 million.
  • As far as peak fluctuations go, Theravance Biopharma's Common Equity tumbled by 13630.96% in 2021, and later skyrocketed by 24851.36% in 2022.
  • Over the past 5 years, Theravance Biopharma's Common Equity (Quarter) stood at -$338.6 million in 2021, then surged by 230.49% to $441.8 million in 2022, then plummeted by 51.79% to $213.0 million in 2023, then fell by 17.58% to $175.5 million in 2024, then surged by 32.55% to $232.7 million in 2025.
  • Its last three reported values are $232.7 million in Q3 2025, $224.8 million for Q2 2025, and $166.0 million during Q1 2025.